Artiria Medical is excited to announce that it secured CE Mark for its SmartGUIDE™ 014 guidewire product.

Excellent clinical results and adoption of SmartGUIDE™ 014 with the support of our amazing North American partners.

Artiria Medical is ready to initiate clinical studies using SmartGUIDE in Europe (premarket) and the US (postmarket) following promising first in-human results and FDA clearance.

Dr. Pascal Mosimann, from Inselspital in Bern, share his thoughts on the unmet need and clinical benefits of the SmartGUIDE™ 014 deflectable tip technology.

Artiria Medical, a Swiss neurovascular MedTech company, announces that its real-time deflectable guidewire has been granted the 510(k) clearance by the U.S. Food and Drug Administration (FDA).

Artiria Medical raised CHF 3.8 M, including a CHF 2.7 M grant from the highly selective EIC accelerator program and a CHF 1.1 M bridge financing.